nirmatrelvir - dofaq.co
Optimal timing of nirmatrelvir/ritonavir treatment after COVID-19 symptom onset or diagnosis: target trial emulation
Nature.com - 16 Dec 2023
Optimal timing of nirmatrelvir /ritonavir treatment after COVID-19 symptom onset or diagnosis: target trial emulation ...
Nirmatrelvir fails to shorten COVID-19 symptoms in latest trial
News-Medical.Net - 08 Apr 2024
Nirmatrelvir fails to shorten COVID-19 symptoms in latest trial ...
Speeding COVID-19 symptom recovery may not fall within the realm of nirmatrelvir–ritonavir | Latest news for Doctors ...
MIMS - 29 Apr 2024
Speeding COVID-19 symptom recovery may not fall within the realm of nirmatrelvir –ritonavir | Latest news for Doctors ... ...
The effect of nirmatrelvir-ritonavir on hospital admissions and mortality from COVID-19
IDSA - 21 Dec 2023
The effect of nirmatrelvir -ritonavir on hospital admissions and mortality from COVID-19 ...
Effectiveness and safety of Sanhan Huashi granules versus nirmatrelvir–ritonavir in adult patients with COVID-19: A ...
ScienceDirect.com - 23 Apr 2024
Effectiveness and safety of Sanhan Huashi granules versus nirmatrelvir –ritonavir in adult patients with COVID-19: A ... ...
Paxlovid (nirmatrelvir and ritonavir) for the Treatment of Covid-19
Clinical Trials Arena - 10 Nov 2023
Paxlovid (nirmatrelvir and ritonavir) for the Treatment of Covid-19 ...
Paxlovid Fails to Shorten COVID in Standard-Risk and Vaccinated At-Risk Patients
Medpage Today - 03 Apr 2024
Paxlovid Fails to Shorten COVID in Standard-Risk and Vaccinated At-Risk Patients ...
Paxlovid Doesn't Reduce Most Post-COVID Conditions
Medscape - 30 Oct 2023
Paxlovid Doesn't Reduce Most Post-COVID Conditions ...
COVID-19 viral load rebound can occur after VV116, nirmatrelvir-ritonavir
Medical Xpress - 20 Mar 2024
COVID-19 viral load rebound can occur after VV116, nirmatrelvir -ritonavir ...
Predictors of nirmatrelvir–ritonavir receipt among COVID-19 patients in a large US health system | Scientific Reports
Nature.com - 29 Mar 2024
Predictors of nirmatrelvir –ritonavir receipt among COVID-19 patients in a large US health system | Scientific Reports ...
Nirmatrelvir treatment shows no link to reduced long-COVID risk, study reveals
News-Medical.Net - 08 Jan 2024
Nirmatrelvir treatment shows no link to reduced long-COVID risk, study reveals ...
Nirmatrelvir/ritonavir use in pregnant women with SARS-CoV-2 Omicron infection: a target trial emulation
Nature.com - 01 Nov 2023
Nirmatrelvir/ritonavir use in pregnant women with SARS-CoV-2 Omicron infection: a target trial emulation ...
One in five patients on Nirmatrelvir–Ritonavir experience virologic rebound, new observational study reveals
News-Medical.Net - 16 Nov 2023
One in five patients on Nirmatrelvir–Ritonavir experience virologic rebound, new observational study reveals ...
Comparison of azvudine, molnupiravir, and nirmatrelvir/ritonavir in adult patients with mild-to-moderate COVID-19: a ...
Nature.com - 09 Feb 2024
Comparison of azvudine, molnupiravir, and nirmatrelvir /ritonavir in adult patients with mild-to-moderate COVID-19: a ... ...
One in five individuals taking nirmatrelvir-ritonavir therapy found to experience rebound COVID
News-Medical.Net - 13 Nov 2023
One in five individuals taking nirmatrelvir -ritonavir therapy found to experience rebound COVID ...
Nirmatrelvir/ritonavir and risk of long COVID symptoms: a retrospective cohort study | Scientific Reports
Nature.com - 11 Nov 2023
Nirmatrelvir/ritonavir and risk of long COVID symptoms: a retrospective cohort study | Scientific Reports ...
Study observes virologic rebound in 20% of COVID-19 patients treated with nirmatrelvir-ritonavir
News-Medical.Net - 13 Nov 2023
Study observes virologic rebound in 20% of COVID-19 patients treated with nirmatrelvir -ritonavir ...
Molecular mechanisms of SARS-CoV-2 resistance to nirmatrelvir
Nature.com - 11 Sep 2023
Molecular mechanisms of SARS-CoV-2 resistance to nirmatrelvir ...
The anti-COVID-19 drug Paxlovid crosses biological barriers of the placenta and brain in rats | npj Viruses
Nature.com - 24 Jan 2024
The anti-COVID-19 drug Paxlovid crosses biological barriers of the placenta and brain in rats | npj Viruses ...